Delivery Order SPE2DB24D9144-SPE2DB25FCMZC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL auto-injector units. The delivery order, awarded on August 15, 2025, with an ultimate completion date of September 8, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $28.3K by the Defense Logistics Agency's Medical Supply Chain on August 27, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order is scheduled for completion by September 18, 2025, with no set-aside designation applied. The award represents a discrete fulfillment under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order, awarded on August 14, 2025, with an ultimate completion date of September 5, 2025, represents a specific fulfillment under the company's larger Indefinite Delivery Contract with DLA valued at $499,999,999...
- The Defense Logistics Agency awarded a delivery order valued at $27,395.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector medications. This firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of September 10, 2025, and does not utilize a set-aside designation. The award represents a specific fulfillment under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 20, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. The contract has a ceiling value of $85,611.50 with an ultimate completion date of September 11, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $1,712.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 150 mg/ml autoinjectors, with a period of performance through October 3, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, valued at $6,848.92 with a firm fixed price arrangement, is scheduled for completion by September 9, 2025, and was issued on August 18, 2025. This award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete directly in...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, valued at $1,712.23, was executed on August 22, 2025, with an ultimate completion date of September 15, 2025. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on a full-and-open basis within...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 300 mg/2 ml auto-injector prefilled syringes. The contract, valued at $6,848.92 with a firm fixed-price structure, was awarded on August 13, 2025, with an ultimate completion date of September 4, 2025. This delivery order carries no set-aside designation and will be performed at the company's Park...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,712.23 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 mL auto-injector vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will deliver the product to the same location by the ultimate completion date of September 3, 2025. This delivery order was issued without a set-aside designation and is part of DMS Pharmaceutical...
- SPE2DB24D9144Indefinite Delivery Contract
- SPE2DB24D9144-SPE2DB25FCMZCDelivery Order
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair auto-injectors valued at $1,712.22. This delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, utilizes firm fixed-price pricing and was awarded without set-aside designation. The award is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for Department of Defense healthcare facilities. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business status to compete effectively for DLA contracts covering branded and generic prescription drugs, biologics, and medical consumables. Xolair (omalizumab) is a monoclonal antibody used to treat moderate to severe asthma and chronic urticaria, and this delivery order fulfills immediate medical supply requirements for military health facilities. The company's robust contract portfolio demonstrates consistent capability in distributing specialized pharmaceutical products, including auto-injectors and injectable biologics, directly supporting the Department of Defense's healthcare mission across military medical facilities worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/2/25 |